Cladribine and STAT3 Inhibitor for Multiple Myeloma
Author Information
Author(s): Ma Jian, Wang Shuiliang, Zhao Ming, Deng Xin-Sheng, Lee Choon-Kee, Yu Xiao-Dan, Liu Bolin
Primary Institution: International Medical Centre of PLA General Hospital, Beijing, PR China
Hypothesis
Can cladribine combined with a STAT3 inhibitor effectively inhibit multiple myeloma cell proliferation and induce apoptosis?
Conclusion
Cladribine inhibits multiple myeloma cell proliferation and induces apoptosis, especially in cells with wild-type p53, and its combination with a STAT3 inhibitor enhances these effects.
Supporting Evidence
- Cladribine inhibited cell proliferation of multiple myeloma cells in a dose-dependent manner.
- The IC50 of cladribine for U266, RPMI8226, and MM1.S cells was approximately 2.43, 0.75, and 0.18 μmol/L, respectively.
- Cladribine induced apoptosis in U266 cells in a dose-dependent manner.
- The combination of cladribine and a STAT3 inhibitor significantly promoted apoptosis in all three tested multiple myeloma cell lines.
Takeaway
Cladribine is a medicine that can help fight a type of blood cancer called multiple myeloma, especially when used with another drug that stops a certain protein from helping the cancer grow.
Methodology
The study used MTS-based proliferation assays, flow cytometry for cell cycle analysis, and apoptosis assays with Annexin V staining and ELISA.
Limitations
The study primarily focused on in vitro results, which may not fully translate to in vivo effectiveness.
Statistical Information
P-Value
p<0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website